The present invention relates to a pharmaceutical composition comprising at least one Vitamin of the group D, lycopene, at least one flavonoid, at least one terpene and at least one calcium salt of a (C.sub.1-C.sub.3) carboxylic acid for use in the treatment of one or more menstrual disorders selected from the group consisting of Dysmenorrhea and Premenstrual syndrome (PMS).

The preset invention is directed to ACC particles stabilized by at least one stabilizing agent, a pharmaceutical composition including same, and methods of using same, such as for treating or preventing an acidosis-related disease or condition in a subject in need thereof.

The preset invention is directed to ACC particles stabilized by at least one stabilizing agent, a pharmaceutical composition including same, and methods of using same, such as for treating or preventing an acidosis-related disease or condition in a subject in need thereof.

A method of treating oral pain includes administering an effervescing composition into a user's mouth. The user retains the composition with the mouth closed until the effervescing composition fully dissolves, maintaining greater than ambient pressure in the mouth and releasing only excess gas through the nose.

A method of treating oral pain includes administering an effervescing composition into a user's mouth. The user retains the composition with the mouth closed until the effervescing composition fully dissolves, maintaining greater than ambient pressure in the mouth and releasing only excess gas through the nose.

A method of treating oral pain includes administering an effervescing composition into a user's mouth. The user retains the composition with the mouth closed until the effervescing composition fully dissolves, maintaining greater than ambient pressure in the mouth and releasing only excess gas through the nose.

Provided herein are methods of treating cancer in a patient comprising administering a total daily dose of 240 mg sotorasib to the patient, wherein the cancer is a KRAS G12C mutated cancer. Also provided herein are methods of treating KRAS G12C mutated cancer in a patient comprising administering a total daily dose of 960 mg sotorasib to the patient, and reducing the total daily dose of sotorasib to 480 mg in a patient experiencing an adverse event to the 960 mg dose of sotorasib.

Provided herein are methods of treating cancer in a patient comprising administering a total daily dose of 240 mg sotorasib to the patient, wherein the cancer is a KRAS G12C mutated cancer. Also provided herein are methods of treating KRAS G12C mutated cancer in a patient comprising administering a total daily dose of 960 mg sotorasib to the patient, and reducing the total daily dose of sotorasib to 480 mg in a patient experiencing an adverse event to the 960 mg dose of sotorasib.

A method for producing at least one microneedle containing a vaccine for transdermal delivery of the vaccine to a patient includes preparing microparticles or nanoparticles of encapsulated vaccine by preparing a solution comprising a vaccine antigen and a biocompatible polymer matrix; and spray drying the solution to form the microparticles or nanoparticles. The method includes the further steps of preparing a film composition including at least one pre-polymer solution; preparing a suspension comprising the microparticles or nanoparticles and the film composition; loading the suspension into a 3D printer; printing, via the 3D printer, at least one microneedle made from the suspension; and, converting the pre-polymer solution into a cross-linked biopolymer by exposing the at least one microneedle to UV light. Also disclosed are microneedles containing a vaccine for transdermal delivery.

A method for producing at least one microneedle containing a vaccine for transdermal delivery of the vaccine to a patient includes preparing microparticles or nanoparticles of encapsulated vaccine by preparing a solution comprising a vaccine antigen and a biocompatible polymer matrix; and spray drying the solution to form the microparticles or nanoparticles. The method includes the further steps of preparing a film composition including at least one pre-polymer solution; preparing a suspension comprising the microparticles or nanoparticles and the film composition; loading the suspension into a 3D printer; printing, via the 3D printer, at least one microneedle made from the suspension; and, converting the pre-polymer solution into a cross-linked biopolymer by exposing the at least one microneedle to UV light. Also disclosed are microneedles containing a vaccine for transdermal delivery.